Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
This article was originally published in The Pink Sheet Daily
Executive Summary
Next-generation ritonavir-boosted protease inhibitor is headed into Phase IIb, and if all goes well, could be a significant player in the hepatitis C market.